Abstract-Although dopaminergic medication improves functional mobility in individuals with Parkinson's disease (PD), its effects on walking turns are uncertain. Our goals was to determine whether dopaminergic medication improves preplanned and unplanned walking turns in individuals with PD, compared to healthy controls. Nineteen older adults with mild-to-moderate PD and 17 healthy controls performed one of the following three tasks, presented randomly: walking straight, or walking and turning 180°to the right or left. The walking direction was visually cued before starting to walk (preplanned) or after (unplanned, i.e., 0.6 m before reaching the turning point). Subjects with PD were assessed off dopaminergic medication (OFF) and on dopaminergic medication (ON) medication. Turning strategy (step and spin turns), turning performance (turning distance and body rotation) and walking pattern were analyzed for three turning steps. Irrespective of medication state and turning condition, step and spin turns followed a nearly 50:50 distribution. After intake of dopaminergic medication, subjects with PD increased their turning distance but not the amount of body rotation or their walking pattern. Compared to controls, turning impairments in subjects with PD remained while ON medication and problems regulating step width were the most prominent features of their walking pattern. Specifically, subjects with PD turned with narrower cross-over steps, i.e. when the external foot crossed over the line of progression of the internal leg. We conclude that turning impairments remained even after dopaminergic medication and problems modulating step width appears to be a critical feature for turning in PD. Ó 2016 Published by Elsevier Ltd on behalf of IBRO.
INTRODUCTION
For individuals with Parkinson's disease (PD), turning impairments are common features of gait disturbance which is, for many, a trigger to freezing of gait, falls and declined level of societal participation (Stack and Ashburn, 1999; Bloem et al., 2001; Ashburn et al., 2008) . Even if turning difficulties increase with disease progression, more than 50% of people in mild-tomoderate stages of PD report turning problems (Nieuwboer et al., 1998; Bloem et al., 2001) . Turning in PD is characterized by impaired axial coordination (Crenna et al., 2007; Huxham et al., 2008b; Spildooren et al., 2013) , excessive reduction of spatial gait parameters (Huxham et al., 2008a; Mak et al., 2008 ) and a greater number of steps required for turning Ashburn, 2005, 2008; Crenna et al., 2007; Huxham et al., 2008b) . Although the aforementioned studies provided a detailed description of turning impairments in PD, this knowledge predominantly reflects preplanned turns, where the walking direction is known in advance. However, the need to turn in response to a given stimuli, such as turning to circumvent an unexpected obstacle, is a common unpredictable condition occurring on a daily basis. Contrasting preplanned turns, unplanned turning limits the time for planning and execution of motor commands (Cao et al., 1997; Patla et al., 1999) , which have shown to induce delayed turning onset and degraded performance in individuals with PD compared to controls (Mak et al., 2008) . Dopaminergic medication has a dramatic clinical effect on motor impairments in PD (Connolly and Lang, 2014) ; however the effects of medication on balance and gait remain uncertain (Bohnen and Cham, 2006; Curtze et al., 2015) . For instance, positive effects of medication on global measures of balance (Franzen et al., 2009; McNeely et al., 2012) and gait in individuals with PD is well documented (O'Sullivan et al., 1998; Shan et al., 2001; Morris et al., 2005; McNeely et al., 2012; McNeely and Earhart, 2013; Curtze et al., 2015) ; but negative effects on postural adjustments (Horak et al., 1996; Hall et al., 2013) and postural sway have also been reported (Bronte-Stewart et al., 2002; Rocchi et al., 2002; Franzen et al., 2012; Curtze et al., 2015) . Turning while walking is a complex task incorporating gait and balance skills, such as deceleration of the forward progression and maintenance of dynamic body stability while continuing the step cycle (Patla et al., 1991 (Patla et al., , 1999 . Unfortunately, information about the effects of medication on walking turns in PD is limited to a few studies focusing on global performance measures (e.g. turning duration) only (Akram et al., 2013; Curtze et al., 2015) . These studies revealed inconsistent results that vary from no improvement (Akram et al., 2013) to moderate improvements (Curtze et al., 2015) . Consequently, little remains known about the effects of dopaminergic medication on walking turns (e.g. turning strategies, performance and regulation of the walking pattern) in individuals with PD.
Thus, the overarching aim of this study was to determine whether dopaminergic medication improves pre-and unplanned turning in individuals with PD. Specifically, we sought to assess the effects of medication on turning initiation (i.e. turning strategy and onset), turning performance (i.e. body rotation, turning distance, trajectory and velocity) and the walking pattern (i.e. step length and width). We hypothesized that medication would improve turning performance for both turning conditions, with smaller effects expected for unplanned turns due to its reactive features requiring quick modification of the walking pattern (Cao et al., 1997; Mak et al., 2008) .
EXPERIMENTAL PROCEDURES Subjects
Nineteen individuals with a clinical diagnosis of idiopathic PD were recruited from a randomized controlled trial (Conradsson et al., 2012) . We also recruited 17 healthy individuals, matched for age and gender, as a control group (Table 1) . The sample size of approximately 20 individuals with PD and controls, respectively, was based on a previous study assessing the effects of dopaminergic medication on turning (McNeely and Earhart, 2011) . The inclusion criteria for both groups were: age !60 years; Mini Mental State Examination score of !24 (Folstein et al., 1975) ; no visual impairments; and no medical condition or recent injury affecting gait or balance. Specific inclusion criteria for PD participants were: currently being treated with stable oral levodopa therapy; Hoehn and Yahr stage 2-3; ability to walk indoors without assistance or a walking aid; and no prior brain surgery, severe dyskinesia or freezing of gait. There were no significant differences for any characteristics between the PD group and the controls (see Table 1 ). This study was approved by the Regional Board of Ethics in Stockholm, and all participants provided written informed consent prior to their enrollment in the study.
Procedures and setup
The PD group was assessed twice, first after overnight withdrawal of medication (OFF, average off time = 16 h, range: 12-22 h) and then approximately one hour after taking their usual morning dose of dopaminergic medication (ON). Both test sessions were performed on the same day, since assessments over two days were not possible for many of the participants. One trained physical therapist assessed motor impairments of all participants before each test session (OFF and ON) by means of the motor section of the unified Parkinson's disease rating scale (UPDRS). The control group also underwent a protocol covering two sessions. In the first session, controls performed the task at comfortable walking velocity. The same protocol was then repeated (2nd session) with controls walking at a pace that matched the comfortable pace of the subjects with PD. Tomlinson et al. (2010) . b The PIGD score is a four-item sub-score (arising from a chair, standing posture, gait and postural stability) calculated from the UPDRS motor assessment. * Significant differences (p 6 0.025) between the OFF and ON medicated states (Wilcoxon signed-rank test). y Significant differences (p 6 0.025) between the PD ON and the control group (Mann-Whitney U test).
For most control subjects, the matched velocity was achieved by instructing controls to walk slower than their comfortable speed. To achieve a matched turning speed, walking speed was assessed with a handheld stopwatch and by counting the number of steps over a distance of two meters prior to the turn. In cases where control subjects deviated from the targeted speed, they were instructed to change their walking speed (i.e. to walk faster or slower). Subsequently, trials from the control group were included if their walking velocity (prior to the intersection positon) was within one standard deviation (SD) of the mean velocity of the PD ON. By using this approach turning characteristics could be compared between PD and the control group without potential velocity bias (Akram et al., 2010; Spildooren et al., 2013) .
Before the start of data collection, practice sessions were performed to familiarize participants with the procedure. The PD and control groups performed two different turning conditions (preplanned and unplanned) in a randomized order. For both turning conditions, participants walked at their comfortable velocity along a 9-meter walking lane where the turning position was indicated by two poles (see circles in Fig. 1A ). For both preplanned and unplanned turns, one of the following three tasks was performed in a randomized order: walking straight, or walking and turning 180°to the right or to the left. Subjects were instructed to walk and turn to the indicated direction without stopping, taking the closest path to the target (see squares in Fig 1A) . Subjects started each trial 4.65 m from the turning intersection, which provided sufficient distance to reach a steady-state straight walking velocity before initiating the turn (Lindemann et al., 2008) . For the preplanned condition, the walking direction was provided by a visual signal before they started to walk whereas for the unplanned condition, the same visual signal returned approximately one step length (0.6 m) prior to the intersection point (i.e. during steady-state walking). The pre-and unplanned turning condition each contained a total of 15 trials per subject (i.e. five trials -in randomized order -for straight walking, right and left turning). The participants were allowed to rest when needed during testing.
Measurements
An eight-camera motion analysis system (Elite 2002, version 2.8.4380; BTS, Milano, Italy) was used to record at 100 Hz the position of 11 spherical retro-reflective markers located on the spinous process of the seventh cervical vertebrae (C7) and bilaterally on the head, acromion, posterior superior iliac spine and heel. Two markers were also positioned on the two poles forming the intersection (see Fig. 1A ). Three-dimensional trajectories of the markers were reconstructed using a tracking system (Tracklab-BTS, Milan, Italy) (Fig. 1A ). Data were processed and filtered (Butterworth low-pass filter: 7-Hz cut-off frequency) using MATLAB software (MATLAB, 7.4.0, MathWorks, Natick, MA, USA).
Data analysis
The outcome variables retained for analysis focused on turning initiation (i.e. turning strategy and onset), turning performance (i.e. body rotation, turning distance, trajectory and velocity) and spatial gait parameters (i.e. step length and width). We focused our analysis on the first three turning steps since about 75% of the subjects with PD reached an 80-120°turn over the first three steps. This turning magnitude is common in daily life activities and is challenging for PD (Huxham et al., 2008a) . The walking direction (straight, right or left) was indicated with a visual signal before walking initiation during preplanned turns and 0.6 m prior to the intersection point during unplanned turns. For the three dimensional motion analysis, reflective markers were attached to 11 anatomical landmarks to represent the segments of head, trunk, pelvis and feet. (B) Gray foot prints indicate the two pre-turning steps and black foot prints represent footstep adjustments for the three turning steps during a step turn (i.e. first turning step equal the turning direction) and a spin turn (i.e. first turning step opposite to the turning direction). The first turning step was identified as the first heel strike that exceeded two standard deviations in medio-lateral displacement of straight walking (i.e. gray area in figure) . (C) Calculation of step width and step length for a right stride.
The turning steps were identified as the first heel strike exceeding two SD in medio-lateral displacement of five straight walking trials (computed for each participant) in the designated turning direction (see Fig. 1B ) (Akram et al., 2010) . Heel strike events were determined based on the velocity profiles of the heel markers (verticalaxis). Similar to Akram et al. (2010) capturing of the first heel strike event for the right and left foot (i.e. three to four steps prior to the intersection point for most subjects) was used as baseline in determining the onset of the first turning step. To discriminate between preparatory turning steps and the actual turning step, the succeeding turning step also needed to exceed 2 SD from the straight walking trial average. As shown by Hase and Stein (1999) , we observed two distinct stepping strategies during turning. As illustrated in Fig. 1B , a turn was defined as a step turn if the first turning step was performed in the direction of turning or as a spin turn if the first turning step was in the opposite direction of turning. The proportion of turning trials using the step strategy was used as an outcome measure. Turning onset latency was calculated relative to the intersection point (i.e. time when the trunk [C7 marker] crossed the intersection point). Therefore, negative onsets for this outcome measure indicates that turning was initiated before reaching the intersection point while positive values reflect turns initiated after passing the intersection.
The magnitude of pelvis rotation at the third turning step was retained for analysis. For the first three turning steps, the turning distance (i.e. the cumulative linear displacements of the C7 marker in the horizontal plane), mean turning velocity (i.e. the first derivative of the tangential displacement of the C7 marker) and mean turning trajectory (i.e. distance in meters between C7 and the markers positioned at the turning pole) were calculated. In accordance with Huxham et al. (2006) the step width and length were calculated by assessing the spatial position of the heel marker at each heel strikes.
Step width was calculated in relation to the line of progression for each stride (corresponding to a straight line connecting the heel marker between each heel strike) and measured as the distance between the opposite foot and the perpendicular line from the line of progression (see Fig. 1C ). Therefore, a negative step width was obtained when the heel strike of the external foot (e.g. right foot during a turn to the left) crossed over and landed medial to the line of progression of the internal leg. As step length during straight walking was shorter for subjects with PD compared to controls (P = 0.012), the step length during turning trials were normalized by subtracting the mean step length of the straight walking trials.
Statistical analysis
All statistical analyses were performed using the STATISTICA software (Statsoft, version 12, Tulsa, OK). Responsiveness of turning performance (body rotation, turning distance, trajectory and velocity) to dopaminergic medication was expressed as Cohen's d effect sizes (ES) (Cohen, 1988) . Positive ES denote changes that are considered an improvement (i.e. toward the control group). A two-way repeated measures analysis of vari- ance (ANOVA) was used to evaluate the effects of medication (PD OFF and PD ON) and turning condition (preplanned and unplanned) on turning initiation (turning strategy and onset) and turning performance. A two-way ANOVA was also used to evaluate the difference between groups (PD ON and controls) and turning condition (preplanned and unplanned). No differences were found between turns to the right or left or turning strategy (spin or step turn) for turning onset and performance. Hoehn and Yahr stages (2-3) were also similar in these outcomes. Thus, these trials/stages were collapsed together for further analysis. Furthermore, as the amplitude of step width and length was differently regulated for step and spin turns, both step length and width were analyzed separately for turning strategies (step and spin turns) and turning conditions (preplanned and unplanned). A two-way repeated measures ANOVA was used to evaluate the effects of medication (PD OFF and PD ON) and steps (turning step 1, 2 & 3) on step width and length. A two-way ANOVA was used to evaluate the difference between groups (PD ON and controls) and steps (turning step 1, 2 & 3). The Greenhouse-Geisser correction was applied in the event of violations of sphericity and Tukey's HSD test whenever a significant interaction effect occurred. Corrections for multiple statistical testing were not used due to the light of criticism of such corrections (e.g. Bonferroni) to minimize the incidence of false negative when examining hypotheses (Perneger, 1998 ). Instead, the significance level was set at p 6 0.025. Data are presented as mean and 95% confidence intervals (95% CI).
RESULTS
ON medication, participants with PD improved 22% in their UPDRS motor score and 21% in their Postural Instability and Gait Difficulty score as compared to OFF medication (Table 1, P < 0.010). As illustrated in table 1, the mean straight walking velocity improved by 0.07 m/s after medication intake along with a 0.03 m increase in step length (Table 1, P < 0.010). Still, individuals with PD ON medication walked slower with shorter steps as compared to controls (P < 0.001).
Turning initiation
Overall, we found a nearly 50:50 distribution between step and spins during both pre-and unplanned conditions ( Table 2 ). The strategies used for turning did not change with medication (PD OFF vs. ON) and were similar between PD ON and controls. Preplanned turns were initiated prior to the intersection while unplanned turns were initiated after crossing the intersection point (Fig. 2) . Whether OFF or ON medication, subjects with PD initiated their turns with similar latency. Turning onset occurred earlier for PD ON (0.16 sec), in contrast to control subjects in the preplanned condition (group Â condition: P < 0.001); however, no difference in onset between groups for the unplanned turns was found.
Turning performance
In both PD and controls, mean turning velocity was at least twice as high during preplanned turns (0.45-0.47 m/s), compared to unplanned turns (0.18-0.22 m/s) (P < 0.001, Table 2 ). In contrast, the slower unplanned turns led to a larger degree of body rotation at the third turning step (100-113°) compared to preplanned turns (77-99°) (P < 0.001, Table 2 ).
Medication increased turning distance by 5% for preand unplanned turns (p = 0.003), still controls demonstrated 17-19% greater turning distance compared to PD ON (P < 0.001, Table 2 ). Medication did not have any effect on body rotation (P = 0.099), and controls obtained 10-24% higher body rotation compared with PD ON (group: P < 0.001). There were no effects of medication or differences between PD ON and controls on turning trajectory and velocity (P > 0.559). The effects of medication or group (PD ON and controls) were independent of the type of turn performed (medication/group Â turning condition: P > 0.132).
Regulation of step width
For PDs and controls, a general pattern of alternating step width amplitude was observed, i.e. widening -crossingover -widening the base of support for step turns and crossing-over -widening -crossing-over the base of support for spin turns (Fig. 3A, B) .
When using the step strategy during pre-and unplanned turns, significant interaction effects were found for step width (medication Â step interaction: P = 0.024 and P = 0.003, respectively), still post-hoc testing did not reveal any significant differences between PD OFF and ON. There were no effects of medication on step width for the spin strategy. During step turns control subjects crossed their external foot further away from the line of progression of the internal foot compared to PD ON (group Â step interaction: P < 0.001). Specifically, for the second turning step using step turns, the step width of controls was 0.07 m (48-82%) greater (i.e. increased negative step width) compared to PD ON for both turning conditions (preplanned: P = 0.016, unplanned: P = 0.006). For spin turns, the comparison between PD ON and controls revealed a different result for pre-and unplanned turns. For the unplanned condition, PD ON did not cross-over as much as controls (group Â step interaction: P < 0.001), which was evident in the 0.07-0.08 m (67%) greater negative step width in controls for the first (P = 0.001) and third turning step (P < 0.001). In contrast, there were no group differences for the preplanned condition.
Regulation of step length
As illustrated in Fig. 4A , B, both PDs and controls consistently reduced their step length in all conditions during turning, compared to straight walking. Irrespective of medication state, subjects with PD demonstrated a similar reduction of step length while performing step and spin turns. Compared to controls however, PD ON further reduced their step length by 33-36% using step turns during the pre-(group: P = 0.006) and unplanned condition (group: P = 0.019, Fig. 4A ). PD ON also demonstrated 33% higher step length reduction for the second turning step during the unplanned condition while using spin turns compared to controls (group Â step interaction: P = 0.004, Fig. 3B ). There were no group differences for step length reduction using spin turns during the preplanned condition.
DISCUSSION
This is the first study to evaluate the effects of dopaminergic medication on pre-and unplanned turns while walking in individuals with PD. After intake of dopaminergic medication, subjects with PD increased the turning distance but not the amount of body rotation. Regardless, dopaminergic medication did not improve turning performance of individuals with PD to the level of the control group. These residual turning impairments were accompanied by narrower, cross-over steps during turning, which should be considered and addressed during rehabilitation and in fall prevention programs of individuals with PD. Consistent with previous studies (McNeely and Earhart, 2011; Curtze et al., 2015) , turning performance while on medication did not reach that of the control group. Our results indicate that these persisting impairments are related to poor effects of medication on step width and length. Furthermore, problems regulating step width, not step length as previously been emphasized in PD (Hulbert et al., 2014) , were the most prominent differences between PD and controls in their walking pattern. In particular, individuals with PD turned with narrower steps while using a crossing step (i.e. step width closer to a value of zero). Crossing steps while turning is not only a complex motor task that could induce instability due to the drastic change of the base of support, but is also an important contributor to body rotation (Huxham et al., 2008a) . Consequently, problems modulating step width in PD Step width (meter) of three turning steps for PD-OFF, PD-ON and control group while using (A) step and (B) spin turns during the pre-and unplanned condition. Positive values reflect widening of the base of support whereas negative values reflect crossing-over of the base of support (i.e. when the external foot crossed over and landed medial compared to the line of progression of the internal foot). Error bars represent 95% confidence interval. compromise medio-lateral stability (Horak et al., 2005; King and Horak, 2008) and force production necessary to accelerate the center of mass toward the turn direction (Mak et al., 2008) . In line with our findings, narrower step width in PD has been observed during postural reactions (Horak et al., 2005; King and Horak, 2008) and walking turns (Huxham et al., 2008a; Mak et al., 2008) . It is likely that problems modulating step width restrict the performance of turning, as seen in our data, and lead to instability and falls in individuals with PD during everyday living. As previously suggested by King and Horak (2008) , this finding highlights the importance of targeting medio-lateral stability during rehabilitation sessions in individuals with PD.
Walking turns involve an interaction between the linear component (i.e. forward progression of the body) and the angular component (i.e. rotation in relation to the longitudinal axis) (Goodworth et al., 2012) . Our results showed better responsiveness to dopaminergic medication for the linear component compared to the angular component of turning. Although previous findings reporting similar effects of dopaminergic medication on the performance of turning-in-place (Franzen et al., 2009; McNeely and Earhart, 2011) and walking turns in individuals with PD (Curtze et al., 2015) , the divergent effect of medication on linear and angular components of walking is a novel finding. Increased functional connectivity between cortical and sub-cortical brain areas has been demonstrated during turning compared to straight walking in PD (Gilat et al., 2015) . Our current findings imply that the linear and angular component of locomotion likely involve distinct brain networks with potential varying sensitivity to dopaminergic medication. This notion is also supported by a recent study of Curtze et al. (2015) reporting smaller effects of dopaminergic medication on walking turns (ES = 0.20-0.50) compared to straight walking (ES > 0.50).
In contradiction to our hypothesis, the effects of medication on turning performance were not influenced by the availability of time for planning the turn (i.e. pre-vs. unplanned condition). Less effects of medication were expected for the unplanned turns because of their more reactive nature requiring quick modification of the walking pattern (Cao et al., 1997) , which adds stress to impaired executive functioning in PD (i.e. rapid information processing to regulate the motor commands) (Dirnberger and Jahanshahi, 2013) . Impaired executive functioning has shown to be ineffectively treated with dopaminergic medication in individuals with PD (Michely et al., 2012) . On the other hand, the unplanned turn was triggered and guided by a visual cue, which by itself could have facilitated turning as previously reported for other tasks (Mak and Hui-Chan, 2005; Nieuwboer et al., 2009) .
We aimed to capture realistic turning behavior without spatial restrictions and found a nearly 50:50 distribution between step and spin turns. This finding is in contrast to previous studies of healthy adults in that spin turns were more common during preplanned turns (Akram et al., 2010) , while step turns have shown to be more common during challenging turns (e.g. unplanned turns) (Patla et al., 1991; Akram et al., 2010) . Instead, the overall mixed pRef. between step and spin turns found in the present study could represent a sustained flexible repertoire of movement strategies. Furthermore, turning was initiated in a similar manner whether OFF or ON Fig. 4 . Mean normalized step length for three turning steps using (A) step and (B) spin turns during the pre-and unplanned condition for PD-OFF, PD-ON and control group.
Step length data represent the absolute difference between straight walking and turning, i.e. negative values reflect shorter steps length while turning compared to straight walking. Error bars represent 95% confidence interval. medication; however, the control group initiated their turn 64% later during preplanned turns compared to PD ON. This finding may be a compensatory strategy adopted by individuals with PD in accounting for the poor responsiveness of dopaminergic medication to turning we observed, or because of balance impairments or difficulties with modifying an ongoing motor command (Chong et al., 2000; Mak et al., 2008) .
This study aimed to determine whether dopaminergic medication improves turning in individuals with mild-tomoderate PD who do not present with freezing of gait. Therefore, these results can only be generalized to this specific population. Still, as turning is an important factor in triggering freezing of gait episodes, future studies should investigate the effects of medication on turning in individuals who report freezing of gait. All subjects with PD were tested on the same day and in a fixed order (OFF first), which may have led to an underestimation of the medication effect (e.g. fatigue) or to an overestimation induced by a practice effect from repeated testing. Thus, to address the potential risk of fatigue and a practice effect, brief resting sessions were allowed during testing and practice sessions were performed prior to testing, respectively. Furthercontradicting a practice effect -turning performance did not systematically improve across the number of trials in PD OFF and ON (data not reported). Furthermore, while all subjects with PD were confirmed responders to dopaminergic medication (indicated by improved UPDRS-motor, PIGD score and straight line walking), the level of responsiveness to medication was not an inclusion criterion, as in other studies (McNeely and Earhart, 2011; McNeely et al., 2012) . This may limit the generalization and interpretation of these results. Finally, in contrast to several previous studies of turning in PD (Mak et al., 2008; Akram et al., 2013; Curtze et al., 2015) , the controls' walking velocity was matched to that of the PD subjects. Thus, the differences we observed in turning with PD are attributed to the disease itself rather than walking speed.
CONCLUSIONS
Dopaminergic medication appears to increase turning distance but not the amount of body rotation irrespective of performing preplanned or unplanned walking turns. Turning impairments in individuals with PD on dopaminergic medication did not reach the performance of the control group. These residual turning impairments in individuals with PD were accompanied by narrower cross-over steps during turning. These narrower steps reduce stability and are therefore considered as important targets of rehabilitation in individuals with PD.
